NASDAQ:ARWR Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $36.47 +1.18 (+3.34%) (As of 02/2/2023 01:17 PM ET) Add Compare Share Share Today's Range$35.47▼$36.9050-Day Range$28.00▼$40.5652-Week Range$26.81▼$56.25Volume225,538 shsAverage Volume1.06 million shsMarket Capitalization$3.89 billionP/E RatioN/ADividend YieldN/APrice Target$59.22 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside62.4% Upside$59.22 Price TargetShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.50Based on 8 Articles This WeekInsider TradingSelling Shares$4.05 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.16) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector167th out of 1,030 stocksPharmaceutical Preparations Industry74th out of 502 stocks 4.4 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.22, Arrowhead Pharmaceuticals has a forecasted upside of 62.4% from its current price of $36.47.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.52% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 2.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 2.5 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arrowhead Pharmaceuticals this week, compared to 1 article on an average week.Search Interest27 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,050,435.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions65.46% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.16) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -21.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -21.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 9.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arrowhead Pharmaceuticals (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.Read More Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesJanuary 27, 2023 | reuters.comARWR.C - | Stock Price & Latest News | ReutersJanuary 27, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:ARWR)February 2, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.January 26, 2023 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Forecasted to Post Q1 2023 Earnings of $0.16 Per ShareJanuary 25, 2023 | finance.yahoo.comArrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter ResultsJanuary 12, 2023 | reuters.comARWR.MW - | Stock Price & Latest News | ReutersJanuary 9, 2023 | finance.yahoo.comArrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease StudyJanuary 9, 2023 | markets.businessinsider.comArrowhead, Takeda Announce Positive Results From Sequoia Phase 2 Study Of FazirsiranFebruary 2, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.December 20, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Announces $25 Million Milestone Payment from AmgenNovember 30, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Fusion Pharmaceuticals (FUSN)November 30, 2022 | finance.yahoo.comARWR: Sells Olpasiran Royalty Interest for $250 Million…November 23, 2022 | finance.yahoo.comWe Think Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Easily Afford To Drive Business GrowthNovember 13, 2022 | seekingalpha.comArrowhead Pharmaceuticals (ARWR) Presents at AHA Scientific Sessions 2022August 6, 2022 | benzinga.comArrowhead Pharmaceuticals: Q3 Earnings InsightsAugust 4, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter ResultsJuly 20, 2022 | finance.yahoo.comArrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter ResultsJuly 1, 2022 | seekingalpha.comMy 26 Stock $336k Portfolio Outperforms The Market In Horrendous June Because Of This Key TradeJune 30, 2022 | nasdaq.com5 Top Biotech Stocks To Watch In July 2022June 28, 2022 | seekingalpha.comArrowhead Pharma: We Can Afford To Wait For More ProofJune 27, 2022 | bizjournals.comMilliporeSigma opens $65 million facility in VeronaJune 27, 2022 | finance.yahoo.comDrug reduces mutant protein that can lead to fibrosis in rare genetic liver diseaseJune 16, 2022 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its BusinessJune 16, 2022 | nasdaq.comRelative Strength Alert For Arrowhead PharmaceuticalsMay 10, 2022 | investing.comArrowhead Pharmaceuticals Inc. Tops Q2 EPS by 44cMay 9, 2022 | bizjournals.comArrowhead breaks ground on up to $250M Verona project, will receive incentivesMay 2, 2022 | finance.yahoo.comArrowhead Pharmaceuticals to Participate in Upcoming May 2022 ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Company Calendar Last Earnings11/28/2022Today2/02/2023Next Earnings (Confirmed)2/06/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees329Year FoundedN/APrice Target and Rating Average Stock Price Forecast$59.22 High Stock Price Forecast$90.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+62.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,060,000.00 Net Margins-71.01% Pretax Margin-71.01% Return on Equity-40.23% Return on Assets-24.80% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.92 Sales & Book Value Annual Sales$243.23 million Price / Sales16.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.95 per share Price / Book9.23Miscellaneous Outstanding Shares106,710,000Free Float102,972,000Market Cap$3.89 billion OptionableOptionable Beta1.02 Key ExecutivesChristopher Richard AnzalonePresident, Chief Executive Officer & DirectorPatrick C. O'brienCOO, Secretary & Chief Compliance OfficerKenneth Allen MyszkowskiChief Financial OfficerJavier San MartinChief Medical OfficerPeter CarignanVice President-Clinical OperationsKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDMaravai LifeSciencesNASDAQ:MRVICytokineticsNASDAQ:CYTKPTC TherapeuticsNASDAQ:PTCTZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsCWM LLCSold 17,759 shares on 2/1/2023Ownership: 0.085%State of New Jersey Common Pension Fund DBought 12,245 shares on 2/1/2023Ownership: 0.074%Bank of Montreal CanBought 2,822 shares on 2/1/2023Ownership: 0.015%Zurcher Kantonalbank Zurich Cantonalbank Bought 1,582 shares on 2/1/2023Ownership: 0.014%New York State Common Retirement FundBought 3,200 shares on 1/30/2023Ownership: 0.330%View All Insider TransactionsView All Institutional Transactions ARWR Stock - Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price forecast for 2023? 9 brokerages have issued 1 year price objectives for Arrowhead Pharmaceuticals' shares. Their ARWR share price forecasts range from $31.00 to $90.00. On average, they anticipate the company's stock price to reach $59.22 in the next year. This suggests a possible upside of 67.8% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts. How have ARWR shares performed in 2023? Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR stock has decreased by 13.0% and is now trading at $35.29. View the best growth stocks for 2023 here. When is Arrowhead Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023. View our ARWR earnings forecast. How can I listen to Arrowhead Pharmaceuticals' earnings call? Arrowhead Pharmaceuticals will be holding an earnings conference call on Monday, February 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings results on Monday, November, 28th. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.24. The biotechnology company had revenue of $31.58 million for the quarter, compared to analyst estimates of $107.60 million. Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative trailing twelve-month return on equity of 40.23%. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Western Financial Corp CA (0.77%), New York State Common Retirement Fund (0.33%), International Assets Investment Management LLC (0.09%), CWM LLC (0.08%), State of New Jersey Common Pension Fund D (0.07%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $35.29. How much money does Arrowhead Pharmaceuticals make? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.77 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis. How many employees does Arrowhead Pharmaceuticals have? The company employs 329 workers across the globe. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401. This page (NASDAQ:ARWR) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.